survodutide mastery course
Unit 11 of 12
Regulatory Pathway and Future
FDA Breakthrough, EMA PRIME, and the road from Phase 3 to approval
The Regulatory Landscape
Survodutide holds FDA Breakthrough Therapy designation for MASH and EMA PRIME designation, both of which accelerate the review process. This unit covers the regulatory designations, the Boehringer Ingelheim and Zealand Pharma partnership, the projected approval timeline, and what comes after Phase 3.
Interactive Regulatory Tracker
Explore regulatory designations, milestones, and the path to market approval.
regulatory designation tracker
key numbers
regulatory designations and projected milestones.
3
breakthrough/priority designations (FDA, EMA, China CDE)
2023
FDA Fast Track designation (MASH)
2024
FDA Breakthrough Therapy (MASH F2-F3)
2027-2028
projected first approvals
Regulatory designations (Breakthrough Therapy, PRIME, Fast Track) do not guarantee approval. They accelerate the review process and provide development guidance, but the final approval decision depends on Phase 3 trial outcomes. Projected timelines are estimates based on publicly available information and may shift.
key terms
regulatory pathway vocabulary for this unit. tap to expand.
B
FDA grants this when preliminary clinical evidence shows substantial improvement over existing treatments for serious conditions. Benefits include intensive FDA guidance, rolling NDA review, senior management involvement, and eligibility for priority review (6 months vs 10 months).
P
PRIority MEdicines scheme. The EMA's equivalent of FDA Breakthrough Therapy. Provides early and enhanced scientific dialogue, appointment of a CHMP rapporteur, and accelerated assessment (150 vs 210 days). Enables conditional marketing authorization.
N
New drug application. The formal submission to the FDA requesting approval to market a drug. Contains all preclinical, clinical, manufacturing, and labeling data. Rolling review (available with Breakthrough designation) allows sections to be submitted as completed rather than all at once.
R
A regulatory process where the agency reviews completed sections of an application as they are submitted, rather than waiting for the entire dossier. This can shorten the overall time from submission to approval by months. Available to drugs with Breakthrough or Fast Track designation.
Z
survodutide was invented by Zealand Pharma (Copenhagen) and licensed to Boehringer Ingelheim for global development and commercialization. Boehringer runs all Phase 3 trials and regulatory submissions. Zealand receives milestone payments and royalties.
projected regulatory milestones
the path from Phase 3 data readouts through regulatory submissions and projected approvals.
2026: Phase 3 readouts
SYNCHRONIZE-1 (obesity) read out April 28, 2026: 16.6% mean weight-loss efficacy estimand at 76 weeks; 85.1% achieved ≥5% loss; full data at ADA June 2026. Other SYNCHRONIZE arms and the LIVERAGE 52-week histological endpoint are still pending and will determine remaining submission timing.
2027: MASH NDA/MAA
accelerated approval for MASH possible based on LIVERAGE histological data. FDA rolling review via Breakthrough designation. EMA accelerated assessment via PRIME.
2028: obesity NDA
obesity submission contingent on SYNCHRONIZE results. dual-indication filing anticipated. CVOT completion expected same year.
2031: long-term outcomes
LIVERAGE 7-year clinical outcomes data for traditional MASH approval. confirms whether histological improvement translates to reduced liver-related mortality.